Tier 3 — preclinical

Quercetin as a modulator of xenobiotic metabolism: integrating CYP450 regulation, phase II conjugation pathways, and transporter-mediated drug interactions

Seerwan Hamadameen Sulaiman, Rebaz Anwar Omer, Hunar Yasin Muhammad, Amjad Mahmood Qadir, Hemn A H Barzani
European journal of clinical pharmacology 2026 82(11):263

Bibliography

PubMed
PMID 42827146
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: Declarations. Ethics and consent to participate: Not applicable. This manuscript is a review of previously published literature and does not involve original studies with human participants, human tissues, identifiable personal data, or animals conducted by the authors. Therefore, ethics committee approval and informed consent to participate were not required. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing financial or non-financial interests.

Study snapshot

DesignSystematic review of human and mechanistic drug-metabolism evidence
ModelMixed human and preclinical evidence synthesis
SampleClinical pharmacokinetic and laboratory studies; no new participant cohort
InterventionQuercetin effects on CYP enzymes, conjugation pathways, and drug transporters
DurationLiterature available at publication in 2026
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2026, this source examined safety, interactions and special populations. Design: Systematic review of human and mechanistic drug-metabolism evidence. Sample/model: Clinical pharmacokinetic and laboratory studies; no new participant cohort. The exposure or intervention was Quercetin effects on CYP enzymes, conjugation pathways, and drug transporters. Follow-up or treatment period: Literature available at publication in 2026.

Interaction direction and magnitude depended on substrate, exposure, and metabolic or transporter pathway; only a limited set had demonstrated human effects.

Most predicted interactions remain insufficiently characterized clinically. Laboratory inhibition does not establish a predictable interaction for every medicine.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Interaction direction and magnitude depended on substrate, exposure, and metabolic or transporter pathway; only a limited set had demonstrated human effects.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin effects on CYP enzymes, conjugation pathways, and drug transporters; Literature available at publication in 2026.

What this study can and cannot tell us

  • Most predicted interactions remain insufficiently characterized clinically. Laboratory inhibition does not establish a predictable interaction for every medicine.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

10 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified